Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$235.73 USD

235.73
92,022

+1.35 (0.58%)

Updated Nov 7, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

PerkinElmer's (PKI) Latest Kit to Boost COVID-19 Surveillance

by Zacks Equity Research

PerkinElmer's (PKI) newest addition to its SARS-CoV-2 testing portfolio is expected to aid in combating the pandemic by boosting surveillance.

Edwards (EW) States Long-Term Strategy, Provides 2022 View

by Zacks Equity Research

Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.

Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.

QIAGEN (QGEN), Denovo to Develop CDx Test for Lymphoid Cancer

by Zacks Equity Research

QIAGEN (QGEN) will develop a diagnostic assay that can identify the Denovo Genomic Marker 1 in patients with lymphoid cancer.

BD's (BDX) Tissuemed Buyout to Boost its Surgical Solutions Arm

by Zacks Equity Research

BD's (BDX) latest acquisition is expected to complement its currently used products and help to support minimally invasive surgeries.

Is LabCorp (LH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

by Zacks Equity Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.

Are Investors Undervaluing These Medical Stocks Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Exact Sciences' (EXAS) Oncotype DX Test Study Data Favorable

by Zacks Equity Research

Exact Sciences' (EXAS) recent study analysis validates that the Oncotype DX test helps identify early-stage, node-positive breast cancer who can avoid chemotherapy in most women.

LH vs. WST: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LH vs. WST: Which Stock Is the Better Value Option?

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic deals.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN) on strong third-quarter results and raised 2021 guidance.

Here's Why You Should Invest in AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.

CVS Health (CVS) New Alliance to Boost Digital Transformation

by Zacks Equity Research

CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.

Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools

by Zacks Equity Research

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.

Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases

by Zacks Equity Research

Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Quest Diagnostics (DGX) Expands Testing Suite With NGS Test

by Zacks Equity Research

Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.

Here's Why You Should Invest in NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR.